bpc-157 fda news Peptide Crackdown: What Compounding Pharmacists Need to Know FDA to Weigh Easing Limits
Description
is a sterile solution developed by Bioaxa, designed for intramuscular (IM) or intravenous (IV) administration

After initial dissolution, the solution can be diluted with PBS or the appropriate assay buffer
Ishikawa 2012)
Some mild and short-lived side effects can include: Mild soreness or redness at the injection site A feeling of warmth after the injection A short-lived mild headache Feeling slightly flushed Serious reactions are very rare